Michael Adler

Title: Michael Adler - Innovator in Pharmaceutical Formulations

Introduction

Michael Adler is a notable inventor based in Lörrach, Germany. He has made significant contributions to the field of pharmaceuticals, particularly in the development of antibody formulations. His work focuses on enhancing the delivery and stability of therapeutic agents.

Latest Patents

Adler holds a patent for "Subcutaneous anti-HER2 antibody formulations and uses thereof." This invention pertains to a highly concentrated and stable pharmaceutical formulation of anti-HER2 antibodies, such as Trastuzumab (HERCEPTIN™) and Pertuzumab. The formulation is designed for subcutaneous injection and includes a hyaluronidase enzyme, buffering agents, stabilizers, and nonionic surfactants. The patent outlines methods for preparing these formulations and their various applications in medical treatments.

Career Highlights

Michael Adler is currently associated with Genentech, Inc., a leading biotechnology company known for its innovative approaches to drug development. His work at Genentech has been pivotal in advancing therapeutic options for patients with HER2-positive cancers.

Collaborations

Adler has collaborated with esteemed colleagues such as Ulla Grauschopf and Hanns-Christian Mahler. These partnerships have fostered a collaborative environment that enhances the research and development of new pharmaceutical solutions.

Conclusion

Michael Adler's contributions to the field of pharmaceutical formulations demonstrate his commitment to innovation and improving patient care. His patent on anti-HER2 antibody formulations is a testament to his expertise and dedication to advancing medical science.